



How Human Milk Oligosaccharides benefit preterm infants

Up to 50% of preterm babies suffer from feeding intolerance¹

Feeding intolerance is linked to:



Immaturity of the GI system^{1,2}



Disturbed gut microbiota^{3,4}

Goal in neonatal care:


Achieving timely enteral feeding is critical to support healthy growth and development, including the GI tract^{2,5}



First evidence suggests HMOs may reduce morbidity and mortality in preterm infants




Reduced incidence, severity and mortality of NEC*^{6,7}



Reduced risk of gut microbiota dysbiosis**⁸


Preterm infants may have insufficient HMO intake

Mother's own milk




HMO levels may be reduced⁹

Donor human milk



Pasteurisation and sterilisation reduce HMO levels in human milk^{10,11}


Alternative feedings




Do not currently contain HMOs

HMOs Help the Immune Defenses in 4 Main Ways¹²


Promotes the growth of beneficial bacteria



Prevents pathogen adhesion in the gut



Strengthens gut barrier function



Edulates the developing immune system




Symbol Key:
● HMO ● Pathogen ● Glycan on cell surface ● Beneficial bacteria

Evidence suggests that HMOs, 2'FL and LNnT, support timely full enteral feeding and early postnatal growth^{13***}

Supplementing 2'FL and LNnT supports adequate growth outcomes, in line with Fenton growth standards for preterm infants¹³

Weight for age Z scores



Length for age Z scores




Head circumference for age Z scores



**P<0.01

Using 2'FL and LNnT, the mean time to reach full enteral feeding was 2 days shorter^{13†}



*Time to reach full enteral feeding is a reliable indicator of feeding tolerance

Preterm infants are a vulnerable group of neonates which may have insufficient HMO intake. Supplementing the HMO 2'FL and LNnT supports early full enteral feeding and adequate growth in preterm infants.

*Pre-clinical study; **observational study in preterm infants; ***randomised, controlled, clinical study.

FEF, full enteral feeding; FL, fucosyllactose; GI, gastrointestinal; HMO, human milk oligosaccharide; LNnT, Lacto-N-neotetraose; NEC, necrotising enterocolitis.

References: 1. Indrio F, et al. *J Matern Fetal Neonatal Med*. 2011;24 Suppl 1:164-6. 2. Fanaro S. *Early Hum Dev*. 2013;89 Suppl 2:S13-20. 3. Di Mauro A, et al. *Ital J Pediatr*. 2013; 24:39-15. 4. Ford SL, et al. *Am J Clin Nutr*. 2019;109(4):1088-1097. 5. Senterre T. *World Rev Nutr Diet* 2014; 110:201-14. 6. Jantscher-Krenn E, et al. *Gut*. 2012; 61(10):1417-1425. 7. Autran CA, et al. *Br J Nutr*. 2016; 116(2):294-9. 8. Underwood MA, et al. *Pediatr Res*. 2015 Dec;78(6):670-7. 9. Austin S, et al. *Nutrients*. 2019;11(6):1282. 10. Marx C, et al. *J Hum Lact*. 2014;30(1):54-61. 11. Meredith-Dennis L, et al. *J Hum Lact*. 2018;34(1):120-129. 12. Bode L. Human milk oligosaccharides: Every baby needs a sugar mama. *Glycobiology*. 2012;22(9):1147-62. 13. Hascoët JM, et al. Abstract for WCPGHAN 2021.